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Cancer of the esophagus was the eighth most frequently occurring 
type of cancer in 2008, with an estimated 481 400 new diagnoses 
(1). In the same year, there were an estimated 406 000 deaths from 
the disease, making it the sixth most common cancer cause of 
death (1). Despite increasing rates of esophageal adenocarcinomas 
in many Western countries, squamous cell carcinoma of the 
esophagus remains the dominant histological type of esophageal 
cancer worldwide and thus is the focus of this study.
Tobacco smoking and alcohol consumption are considered 
causal for esophageal squamous cell carcinoma, particularly in 
developed countries, where exposure to both of these factors has 
been shown to increase the risk greatly, sometimes multiplicatively 
(2–4). In certain geographic regions with a high incidence of 
esophageal squamous cell carcinoma, most notably in developing 
countries, the risk of esophageal squamous cell carcinoma has been 
found to be associated with local factors, such as poor socioeco-
nomic conditions (5,6); diets low in fruits, vegetables, and specific 
micronutrients such as niacin, vitamins A and C, magnesium, and 
riboflavin (7); low serum selenium levels in China (8); consumption 
of hot tea in South America (9) and Iran (10); the use of certain 
traditional medicinal plants (eg, Solanum nigrum) in Transkei, South 
Africa (11); and consumption of specific opiates (12,13). However, 
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 Background The role of human papillomavirus (HPV) in the causation of esophageal squamous cell carcinoma is unclear. 
We examined the associations between esophageal squamous cell carcinoma and 28 centrally measured HPV 
serological markers in serum from six existing case–control studies conducted in regions with differing background 
risks of esophageal cancer.
Methods We used centralized multiplex serology to test serum samples from 1561 case subjects and 2502 control subjects 
from six case–control studies for antibodies to the major HPV capsid protein (L1) and/or the early proteins E6 
and/or E7 of eight high-risk, two low-risk, and four cutaneous HPV types. Study-specific odds ratios (ORs) and 
corresponding 95% confidence intervals (CIs) were estimated using conditional logistic regression with 
adjustment for smoking, alcohol consumption, and other potential confounders. Pooled odds ratios and 95% 
confidence intervals were calculated using either a linear mixed-effects approach or a joint fixed-effects 
approach. All statistical tests were two-sided.
Results We found statistically significant associations between esophageal squamous cell carcinoma and antibodies to 
E6 for HPV16 (OR = 1.89, 95% CI = 1.09 to 3.29, P = .023) and HPV6 (OR = 2.53, 95% CI = 1.51 to 4.25, P < .001) 
but not for other tested HPV types. There were no statistically significant associations between esophageal 
squamous cell carcinoma and antibodies to E7 for any of the tested HPV types. Simultaneous seropositivity for 
HPV16 E6 and E7 was rare (four case subjects, two control subjects; OR = 5.57, 95% CI = 0.90 to 34.35; P = .064). We 
also found statistically significant associations between esophageal squamous cell carcinoma and capsid anti-
bodies for the high-risk mucosal type HPV33 L1 (OR = 1.30, 95% CI = 1.00 to 1.69; P = .047) and the low-risk mucosal 
types HPV6 (OR = 1.22, 95% CI = 1.05 to 1.42; P = .010) and HPV11 (OR = 1.30, 95% CI = 1.09 to 1.56, P = .0036).
 Conclusions We found limited serological evidence of an association between esophageal squamous cell carcinoma and HPV in 
the populations studied. Although HPV does not appear to be an important risk factor for esophageal squamous cell 
carcinoma, we cannot exclude the possibility that certain HPV types may be involved in a small subset of cancers.
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the lack of known prevalent strong risk factors for esophageal 
squamous cell carcinoma in many high-incidence regions suggests 
that additional important risk factors are yet to be identified.
One possible risk factor for esophageal squamous cell carcinoma 
is infection with oncogenic human papillomavirus (HPV) types. 
HPV type 16 (HPV16) is known to cause the majority of squamous 
cell carcinomas of the cervix (14–17) and is strongly associated 
with subgroups of squamous cell carcinomas at other anogenital 
sites (18,19) and with cancers of the head and neck, particularly 
the oropharynx (20–22). The possibility that HPV might play an 
etiologic role in the development of esophageal squamous cell 
carcinoma was first proposed in 1982 by Syrjänen et al. (23,24) 
based on histological findings that suggested possible associations 
between HPV and both malignant and benign squamous cell 
lesions of the esophagus. Since then, although more than 100 studies 
have investigated the relationship between esophageal squamous cell 
carcinoma and HPV, the evidence of an association is inconclusive 
 CONTEXT AND CAVEATS
Prior knowledge
Infection with oncogenic human papillomavirus (HPV) types has 
been linked to various cancers, including cancers of the head and 
neck. However, the role of HPV in the causation of esophageal 
squamous cell carcinoma is unclear.
Study design
Centralized multiplex serology was applied to serum samples from 
1561 case subjects and 2502 control subjects from six case–control 
studies to detect circulating antibodies against 28 HPV antigens (18 
L1, E6, or E7 antigens from the eight high-risk mucosal HPV types, 
including HPV16 and HPV33; six L1, E6, or E7 antigens from the two 
prevalent low-risk mucosal HPV types, HPV6 and HPV11; and four 
L1 antigens from cutaneous HPV types).
Contribution
There were only a limited number of nominally statistically signifi-
cant associations between esophageal squamous cell carcinoma 
and seropositivity for HPV16 E6, HPV6 E6, HPV33 L1, HPV6 L1, and 
HPV11 L1.
Implications
The limited serological evidence for an association between esoph-
ageal squamous cell carcinoma and HPV in the populations studied 
suggests that HPV is not an important risk factor for esophageal 
squamous cell carcinoma.
Limitations
Inflation of the type I error rate for observing one or more false 
statistically significant test results among all tests performed was 
likely because the analyses were not adjusted for multiple com-
parisons. The results of the contributing case–control studies are 
susceptible to reverse causation. Some study-specific and/or general 
confounders may not have been adequately adjusted for in this 
analysis. Differences in the rates of undiagnosed cervical cancers 
between case subjects and control subjects could confound 
estimates of the associations between seropositivity to the E6 or 
E7 proteins of the high-risk mucosal HPV types and esophageal 
squamous cell carcinoma for women.
From the Editors
 
(25). Arguments in support of an association include 1) the detection 
of HPV DNA in esophageal squamous cell carcinoma (26); 2) the 
histological similarities of the oral and esophageal squamous 
epithelia (27); 3) the proximity of the esophagus and oropharynx 
and their similar neoplastic responses to smoking and alcohol 
(26,27); 4) evidence of an association between HPV and bovine 
esophageal cancer (28); and 5) in vitro transformation of esophageal 
epithelial cells by HPV (29). Arguments against an association 
between esophageal squamous cell carcinoma and HPV include 
the inconsistent conclusions among serological studies of HPV 
and esophageal squamous cell carcinoma and the wide variations in 
the prevalence of HPV DNA detected in esophageal squamous cell 
carcinoma tissue among studies (26).
Serological testing for HPV proteins has been a useful tool for 
identifying and confirming associations between HPV and various 
types of squamous cell cancer (16–22). The presence of circulating 
antibodies to the HPV late capsid protein L1 is considered a 
marker of cumulative (lifetime) exposure to HPV (30) and high 
seropositivity for HPV16 L1 has been shown to be associated with 
increased risks of cancer of the cervix (16,19), the oral cavity (20), 
and the oropharynx (20,22). A number of serological studies have 
examined the association between esophageal squamous cell 
carcinoma and HPV16 L1 or HPV18 L1 antibodies (19,31–36). 
Although all of those studies measured L1 antibodies using similar 
methods, the definitions of seropositivity varied among the studies, 
making comparisons of results between studies difficult. 
Seropositivity for the E6 and E7 proteins of HPV16 and HPV18 
have been shown to be moderately sensitive and highly specific 
markers for HPV-driven carcinomas of the cervix (17), oropharynx 
(20,21), and penis (18), and thus appear to be useful markers 
for identifying patients with HPV-positive tumors. However, the 
statistical power to detect relatively small underlying associations 
between specific cancer types and seropositivity for E6 or E7 
antibodies is limited in case–control studies because invasive 
HPV-driven carcinomas are rare in the populations from which 
control subjects are chosen (17,18,20–22). Thus, it is important to 
consider the absence of a statistical association between esophageal 
squamous cell carcinoma and seropositivity to either E6 or E7 for 
a given HPV type in conjunction with the results for all other 
serological markers of that HPV type.
The evolution of reliable high-throughput multiplex serological 
techniques has allowed the simultaneous testing of up to 100 
different markers using only 2 µL of serum per sample (37–39). The 
aim of this collaboration was to examine the associations between 
the risk of esophageal squamous cell carcinoma and a number of 
HPV serological markers measured using this technology in serum 
from existing case–control studies conducted in regions with dif-
fering background risks of esophageal cancer, after adjustment for 
smoking, alcohol consumption, and other potential confounders. To 
our knowledge, this is the largest study to examine the relationship 
between esophageal squamous cell carcinoma and HPV antibodies, 
the first study to compare HPV E6/E7 seroreactivities of esophageal 
squamous cell carcinoma case subjects with that of control subjects, 
and the first study to examine the relationships between esophageal 
squamous cell carcinoma and antibodies to HPV types other than 
HPV16, HPV18, HPV33, and HPV73 (a very rare type known to 
be associated with cervical cancer but not examined in this study).
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Methods
Selection of Studies
Esophageal squamous cell carcinoma case–control studies that had 
at least 100 case subjects and 100 control subjects were identified 
through review of published studies and supplemented by discus-
sions with investigators of as yet unpublished studies. Those that 
had stored participant serum available for serological HPV anti-
body testing and that had collected data on the major esophageal 
squamous cell carcinoma risk factors, including smoking and 
alcohol consumption, were invited to participate in the InterSCOPE 
collaboration. Six study groups, from South Africa (19), Australia 
(40), Central and Eastern Europe (41), Brazil (42), Iran (13), and 
China (43), agreed to participate and forward their serum samples 
from histopathologically confirmed esophageal squamous cell 
carcinoma case subjects as well as serum samples from one or two 
age- and sex-matched control subjects to the German Cancer 
Research Center (Deutsches Krebsforschungszentrum [DKFZ]) 
within a prespecified time frame for serological analysis. A total 
of 1561 case subjects and 2502 control subjects had complete 
information on all predetermined study-specific confounders (see 
“Definitions of Exposures and Confounders” below) and were thus 
selected for inclusion in this analysis. De-identified questionnaire 
data and serum results were forwarded to the Cancer Epidemiology 
Research Unit at Cancer Council NSW for statistical analysis. The 
participating studies covered a wide range of geographical areas 
and had estimated age-standardized incidence rates of esophageal 
carcinoma (standardized to the world standard population) that 
ranged from approximately 5 per 100 000 in Australia to approxi-
mately 50 per 100 000 in Shanxi Province, China (Table 1). All six 
studies and this pooled analysis were approved by the appropriate 
national or institutional ethics committees or review boards. 
Written or witnessed oral informed consent was obtained from 
participants before interview in South Africa. Written consent was 
obtained from participants before interview in the five remaining 
studies.
Serological Methods
Serum or plasma samples from each study, which were previously 
stored at temperatures ranging from 220°C to 280°C (Table 1), 
were sent on dry ice to DKFZ (Heidelberg, Germany) and stored 
at 220°C until the day of multiplex serological testing, which was 
performed as described in detail elsewhere (37–39). Briefly, 
antigens were bacterially expressed as recombinant double fusion 
proteins with N-terminal glutathione S-transferase (GST) and a 
C-terminal peptide (tag) consisting of the last 11 amino acids from 
the large T antigen of simian virus 40 (48). Bacterial pellets were 
lysed with the use of a high-pressure homogenizer, the lysates were 
cleared of insoluble components by centrifugation, and the resulting 
supernatants were stored with 50% glycerol at 220°C. Fusion 
proteins were characterized by Coomassie-stained sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis, immunoblot analyses 
using GST- and tag-specific antibodies and GST-capture enzyme-
linked immunosorbent assay (48). GST–tag double fusion proteins 
from cleared lysates were affinity-purified in situ through binding 
to glutathione casein–coated fluorescence-labeled polystyrene beads. 
Each fusion protein was bound to a spectrally distinct bead set 
(SeroMAP Microspheres; Luminex Corp, Austin, TX), and the fusion 
protein–loaded bead sets were mixed. Sera were pre-incubated 
at 1:50 dilution in phosphate-buffered saline containing 1 mg/mL 
casein, 2 mg/mL lysate from bacteria expressing GST-tag alone 
(to block antibodies directed against residual bacterial proteins and 
the GST–tag), 0.5% polyvinylalcohol, 0.8% polyvinylpyrrolidone, 
and 2.5% Superchemiblock (Millipore, Billerica, MA) to suppress 
nonspecific binding of antibodies to the beads themselves (39). 
Serum dilutions were incubated with the same volume of mixed 
bead sets, resulting in a final serum dilution of 1:100. Bound anti-
bodies were detected with biotinylated goat anti-human immuno-
globulin G (H + L) secondary antibody and streptavidin-conjugated 
R-phycoerythrin. A Luminex 100 analyzer (Luminex Corp) was 
used to identify the internal color of the individual beads and to 
quantify their fluorescence (expressed as median fluorescence 
intensity [MFI]) of at least 100 beads per set per serum. A fusion 
protein consisting of GST and tag without intervening viral 
antigen served for individual “serum background” determination.
Testing was performed by laboratory staff who were blinded 
to the case–control status of the subjects. Serum samples were 
analyzed for antibodies to the major capsid protein (L1) and/or the 
early oncoproteins E6 and/or E7 of the following HPV types: the 
high-risk mucosal types HPV16 and HPV18 (L1, E6, and E7), and 
HPV31, HPV33, HPV35, HPV45, HPV52, and HPV58 (L1 and 
E6 only); low-risk mucosal HPV types HPV6 and HPV11 (L1, E6, 
and E7); and cutaneous HPV types HPV1, HPV4, HPV49, and 
HPV77 (L1 only) as described previously (37,38). The 10 high- and 
low-risk HPV types analyzed in this study were selected based 
on preexisting evidence of their associations with squamous cell 
carcinoma of the cervix, oral cavity, or oropharynx or with benign 
tumors of the larynx and respiratory epithelium. These HPV types 
were predetermined to be the best candidates for assessing whether 
HPV plays a role in esophageal squamous cell carcinoma. The 
four cutaneous HPV types—for which no tumor association was 
expected—were included primarily as specificity controls. In addition, 
we performed serological testing for antibodies to three non-HPV 
antigens as controls: p53 (a positive control in which seropositivity 
was expected to be associated with esophageal squamous cell 
carcinoma) and the VP1 capsid proteins of two ubiquitous human 
polyomaviruses, Merkel cell virus (MCV) and JC virus (JCV) 
(additional specificity controls) (49). The testing of all sera was 
performed over three consecutive days in 96-well plates, and each 
serum sample was tested once. All sera from any one study were 
tested on the same day. A quality control panel of 188 randomly 
chosen sera was included on each day of testing to determine inter-
day variation. Pearson correlation coefficients (R) of raw MFI 
values for the individual antigens in the quality control samples 
ranged from .76 to .99 (median = .96) for low-prevalence antigens 
(ie, HPV early proteins E6 and E7) and from .93 to .99 (median = 
.97) for high-prevalence antigens (ie, HPV L1 and the control 
antigens). A reference serum with known reactivity to seven 
antigens (HPV16 L1, HPV49 L1, HPV77 L1, HPV16 E6, 
HPV16 E7, JCV VP1, and MCV VP1) was included on each plate 
as a measurement standard. Interplate coefficients of variation for 
this plate standard for the various antigens across the three assay 
days ranged from 13.5% to 19.6% (median = 16.4%), indicating 
low plate-to-plate variation. Autofluorescence of each bead set and 
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background reactions resulting from binding of secondary reagents 
to the antigen-loaded beads (“bead background”) were determined 
in one well per plate without human serum. The antigen-specific 
reactivity of each serum sample was then calculated as the antigen-
specific raw MFI value minus the sum of the mean bead background 
value (averaged over plates) and individual serum background value.
Definitions of Exposures and Confounders
Binary indicators of seropositivity were defined for all serological 
markers that were assessed. We used previously published cutoff 
values to define seropositivity for the L1 antigens of HPV1, 
HPV4, HPV 16, HPV18, HPV31, HPV33, HPV45, HPV49, 
HPV52, HPV58, and HPV77 (37,50). For the remaining antigens 
(the L1 antigens of HPV6, HPV11, and HPV35; the E6 antigens 
of HPV6, HPV11, HPV 16, HPV18, HPV31, HPV33, HPV35, 
HPV45, HPV52, and HPV58; and the E7 antigens of HPV6, 
HPV11, HPV 16, and HPV18), all of which were mucosal sexually 
transmitted HPV types, we used cutoff values to define seroposi-
tivity that were derived from the sera of a group of self-reported 
Korean virgins [algorithm as defined in Clifford et al. (50)]. We 
also constructed four additional composite binary indicator 
variables. In the first variable, subjects were classified seropositive 
if they were seropositive for either HPV16 E6 or E7 or to both 
(hereafter referred to as HPV16 E6 and/or E7 seropositivity). In 
the second variable, subjects were classified as seropositive if they 
were seropositive for both HPV16 E6 and E7 (hereafter referred 
to as HPV16 E6 and E7 seropositivity). In the third variable, 
subjects were classified seropositive if they were seropositive 
for either HPV18 E6 or E7 or to both (hereafter referred to 
as HPV18 E6 and/or E7 seropositivity). In the fourth variable, 
subjects were classified as seropositive if they were seropositive for 
both HPV18 E6 and E7 (hereafter referred to as HPV18 E6 and 
E7 seropositivity).
Multilevel covariates representing cumulative lifetime con-
sumption of alcohol and tobacco smoking were constructed for the 
studies that had sufficient data available on these exposures. For 
these studies, pack-years of smoking were used to represent the 
cumulative lifetime exposure to tobacco smoke and were calculated 
by multiplying the number of packs of cigarettes smoked per day 
by the number of years of smoking. One pack of cigarettes was 
defined as 20 g of tobacco. Similarly, cumulative exposure to 
alcohol was represented by drink-years, which were calculated by 
multiplying the number of alcoholic drinks consumed per day by 
the number of years of drinking. One drink was defined as 15.7 g 
of alcohol (ethanol). These definitions of pack-years and drink-years 
have been used in other studies that examined factors associated 
with esophageal squamous cell carcinoma (51,52). For use as 
covariates in regression analyses examining the associations 
between esophageal squamous cell carcinoma and serological 
markers, cumulative lifetime consumption of alcohol and tobacco 
smoking were categorized as never drank alcohol, 1–79, 80–139, 
140–199 or 200 or more drink-years and never smoker, ex-smoker 
who smoked 1–29 pack-years, ex-smoker who smoked 30 or more 
pack-years, smoker who smoked 1–29 pack-years, or smoker who 
smoked 30 pack-years or more, respectively. A composite alcohol 
and smoking covariate was also created to examine the association 
between esophageal squamous cell carcinoma and combined levels 
of smoking and alcohol consumption with the following cate-
gories: never smoked or drank alcohol, never smoked and 1–79 
drink-years of alcohol exposure, never smoked and 80 or more 
drink-years of alcohol exposure, ever smoked and 1–79 drink-years 
of alcohol exposure, and ever smoked and 80 or more drink-years of 
alcohol exposure. Cut points for the above individual and composite 
alcohol and smoking covariates were chosen so as to provide 1) 
uniformly defined categories across studies with these measures 
and 2) sufficient numbers of case and control subjects within each 
category of each study (to allow reliable estimates of the study-
specific effects of smoking and alcohol) while maintaining an 
adequate number of categories for each covariate (to reduce the 
potential for residual confounding). The use of various other cut 
points satisfying the above mentioned criteria did not produce 
substantive changes in the overall conclusions of this study (data 
not shown).
Exposure to alcohol was defined as ever vs never for Iran, 
China, and South Africa. Exposure to smoking was defined as ever 
vs never for South Africa only (we were also able to construct mul-
tilevel smoking and alcohol covariates for a subset of the South 
African participants who were interviewed using versions of the 
study questionnaire that were designed after 1998).
Variables representing the highest level of education attained 
(none, primary, secondary, or tertiary) and remoteness of residence 
(urban or rural) were uniformly defined and coded across studies. 
Several local study variables were also constructed, including 
opium, nass, and hot tea consumption in Iran; maté consumption 
in Brazil; and snuff use in South Africa.
Statistical Analysis
Study-specific odds ratios (ORs) and corresponding 95% confi-
dence intervals (CIs) were estimated using conditional logistic re-
gression. Fully adjusted study-specific models were adjusted for 
education level (none, primary, secondary, or tertiary for all 
studies), remoteness of residence (rural or urban for all studies), 
opium consumption (never or ever for Iran only), nass consumption 
(never or ever for Iran only), tea consumption (warm/lukewarm, 
hot, or very hot for Iran only), maté consumption (never, cold/
warm, hot/very hot for Brazil only), and snuff use (never or ever 
for South Africa only); and by matched design for age (category 
matched by 5-year age groups for South Africa and Australia; 
directly matched by ±2 years for Iran, by ±5 years for China, and 
by ±10 years for Central and Eastern Europe, and Brazil), sex 
(male, female for all studies), serum storage time (category 
matched by 2-year serum storage times groups for South Africa; 
directly matched by ±1 year serum storage times for Central and 
Eastern Europe, and Brazil only), neighborhood (Iran and China 
only), and study center (Central and Eastern Europe and Brazil 
only). Fully adjusted study-specific models examining the associa-
tions between esophageal squamous cell carcinoma and serological 
markers were additionally adjusted for alcohol consumption (never 
or ever for South Africa, Iran, and China; never drank alcohol, 
1–79, 80–139, 140–199, or ≥200 drink-years for Australia, Central 
and Eastern Europe, and Brazil) and tobacco smoking (never or 
ever for South Africa; never, ex-smoker who smoked 1–29 pack-
years, ex-smoker who smoked ≥30 pack-years, smoker who smoked 
1–29 pack-years, or smoker who smoked ≥30 pack-years for Australia, 
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Central and Eastern Europe, Brazil, Iran, and China). The effects 
of all covariates were modeled categorically.
Pooled odds ratios and 95% confidence intervals were calcu-
lated using either a linear mixed-effects approach or a joint fixed-
effects approach (53). The linear mixed-effects approach calculates 
the pooled odds ratio as a weighted average of the study-specific 
odds ratios with weights equal to the inverse marginal variances. In 
the presence of statistically significant heterogeneity [assessed 
using the residual heterogeneity statistic (54)], the marginal 
variance is calculated as the sum of the study-specific variance and 
the additional unexplained variance of exposure effects across 
studies (53). In the absence of statistically significant heterogeneity, 
the marginal variance is equal to the study-specific variance. 
Although the linear mixed-effects approach is generally the 
preferred method for pooling case–control data (53), it cannot be 
used if one or more studies have undefined odds ratios due to the 
absence of at least one seropositive or seronegative, case or control 
subject. In such circumstances, we estimated the pooled odds ratios 
by analyzing the combined data in a single conditional logistic 
regression model (also known as a joint fixed-effects approach). 
Smoking and alcohol exposures were categorized as ever vs never, 
and all study-specific covariates (snuff, maté, hot tea, nass, and 
opium consumption) were excluded from analyses using the joint 
fixed-effects approach because it requires uniformly defined 
covariates across studies. The nominal P value is shown for each 
statistical test without adjustment for multiple comparisons. All 
statistical tests were two-sided, and statistical significance was 
defined as P less than .05. All analyses were performed using 
STATA 11 software (StataCorp 2010 Statistical Software: release 
11·0, STATA: College Station, TX).
We performed a series of sensitivity analyses to assess the 
robustness of the results. First, we estimated minimally adjusted 
associations between esophageal squamous cell carcinoma and all 
serological markers (ie, adjusted only for the study matching vari-
ables) to examine the overall influence of the full set of potential 
confounders. Second, associations between esophageal squamous 
cell carcinoma and seropositivity for each HPV protein that is 
suspected to cross-react with homologous proteins of phylogenet-
ically related HPV types (ie, species alpha7, comprising HPV types 
HPV16, HPV31, HPV33, HPV35, HPV52, and HPV58; species 
alpha9, comprising types HPV18 and HPV45; and species alpha10, 
comprising types HPV6 and HPV11) were re-estimated after 
excluding subjects who were seropositive to the protein of interest 
and one or more potentially cross-reacting proteins. Third, associ-
ations between esophageal squamous cell carcinoma and all sero-
logical markers were re-estimated after removing data from the 
largest study (South Africa) and also after removing data from the 
two studies in which the blood collection procedures differed for 
the case and control subjects (Iran and China). Fourth, associations 
between esophageal squamous cell carcinoma and all HPV 
markers stratified by smoking (ever vs never), alcohol (ever vs 
never), and sex were estimated using appropriate interaction terms.
Results
A total of 1561 case subjects and 2502 control subjects from the six 
participating studies were included in the primary analyses (Table 1). 
The largest proportion of participants was from the South African 
study (45%), followed by the Australian study (16%). The studies 
from Iran, Central and Eastern Europe, and Brazil each provided 
11%–12% of the participants, and the remaining 6% were pro-
vided by the Chinese study. Overall, participants ranged in age 
from 26 to 91 years and were predominantly male (64%) (Table 2). 
Compared with control subjects, proportionally fewer case sub-
jects were never smokers (34% vs 50%), were educated at the high 
school level or beyond (46% vs 57%), or lived in an urban area 
(62% vs 74%).
The patterns of risk of esophageal squamous cell carcinoma in 
relation to smoking and alcohol consumption were similar to those 
reported in other studies among the subset of participants for whom 
cumulative lifetime consumption of alcohol was available (55,56) 
(Supplementary Figure 1, available online). Compared with individ-
uals who never smoked or drank alcohol, those who ever smoked and 
had 80 or more drink-years of alcohol exposure had an elevated risk 
of esophageal squamous cell carcinoma (OR = 6.13, 95% CI = 4.10 
to 9.15). Compared with individuals who never smoked or drank 
alcohol, those who had ever smoked and reported 1–79 drink-years 
of alcohol exposure had an odds ratio of 2.09 (95% CI = 1.37 to 3.20). 
Compared with individuals who never smoked or drank alcohol, 
never smokers who had 80 or more drink-years of alcohol exposure 
and never drinker–ever smokers had odds ratios of 1.46 (95% CI = 
0.68 to 3.16) and 1.77 (95% CI = 0.76 to 4.12), respectively. Among 
never smokers, those who had 1–79 drink-years of alcohol exposure 
had a lower risk of esophageal squamous cell carcinoma compared 
with never drinkers (OR = 0.60, 95% CI = 0.39 to 0.90).
Associations With Serological Markers
Table 3 shows the pooled fully adjusted odds ratios of esophageal 
squamous cell carcinoma and 95% confidence intervals associated 
with each of the 35 serological markers. Figure 1 shows the pooled 
odds ratios adjusted only for study matching variables (left panel) 
and after full adjustment (right panel). Supplementary Table 1 
(available online) shows the study-specific results.
HPV Early Protein Markers (E6 and E7). We found statistically 
significant associations between esophageal squamous cell carci-
noma and seropositivity for E6 for the high-risk mucosal type 
HPV16 (OR = 1.89, 95% CI = 1.09 to 3.29; P = .023) and for the 
low-risk mucosal type HPV6 (OR = 2.53, 95% CI = 1.51 to 4.25; 
P < .001) but not for any of the other HPV types (ORs ranged from 
1.18 to 3.92 and P values ranged from .065 to .65) (Table 3). The 
odds ratios for the associations between esophageal squamous cell 
carcinoma and E6 antigens of the high-risk mucosal types HPV33 
and HPV52 were 2.76 (95% CI = 0.86 to 8.82; P = .087) and 3.92 
(95% CI = 0.92 to 16.74; P = .13), respectively. There were no 
statistically significant associations between esophageal squamous 
cell carcinoma and E7 seropositivity for HPV types HPV6, HPV11, 
HPV16, or HPV18. Double seropositivity for HPV16 E6 and E7 
was rare and was not associated with esophageal squamous cell car-
cinoma (4/1561 case subjects, 2/2502 control subjects; OR = 5.57, 
95% CI = 0.90 to 34.35; P = .064). Double seropositivity for HPV18 
E6 and E7 was even more rare and was also not associated with 
esophageal squamous cell carcinoma (2/1561 case subjects, 1/2502 
control subjects; OR = 3.52, 95% CI = 0.31 to 39.48; P = .31).
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HPV Late Protein Markers (L1). We found statistically significant 
associations between esophageal squamous cell carcinoma and 
seropositivity for L1 for the high-risk mucosal type HPV33 (OR = 
1.30, 95% CI = 1.00 to 1.69; P = .047) and the low-risk mucosal 
types HPV6 (OR = 1.22, 95% CI = 1.05 to 1.42; P = .010) and 
HPV11 (OR = 1.30, 95% CI = 1.09 to 1.56; P = .0036). The odds 
ratios for the associations between esophageal squamous cell carci-
noma and L1 antigens of the high-risk mucosal types HPV16 and 
HPV18 were 1.20 (95% CI = 0.97 to 1.47; P = .092) and 1.28 (95% 
CI = 0.93 to 1.75; P = .13), respectively. We found no statistically 
significant associations between esophageal squamous cell carci-
noma and L1 seropositivity for HPV types HPV1, HPV4, HPV31, 
HPV35, HPV45, HPV49, HPV52, HPV58, or HPV77 (ORs 
ranged from 0.92 to 1.18, P values ranged from .055 to .82). The as-
sociation between esophageal squamous cell carcinoma and HPV18 
L1 showed statistically significant heterogeneity among the six 
studies (Pheterogeneity = .0085; Supplementary Table 1, available online); 
none of the other HPV markers examined using the linear mixed-
effects approach showed any statistically significant heterogeneity.
Other Serological Markers. As expected, we found a strong 
association between esophageal squamous cell carcinoma and p53 
seropositivity (OR = 8.10, 95% CI = 3.83 to 17.17; P < .001). There 
was statistically significant heterogeneity in the association between 
p53 seropositivity and esophageal squamous cell carcinoma, with an 
odds ratio of 3.01 (95% CI = 2.14 to 4.44) in the South Africa study, 
where control subjects were people with other cancers, and an odds 
ratio of 40.64 (95% CI = 9.26 to 178.38) in the Australia study, 
where disease-free control subjects were used (Supplementary 
Table 1, available online). No positive associations were found 
between esophageal squamous cell carcinoma and the VP1 capsid 
protein of human polyomaviruses JCV (OR = 0.86, 95% CI = 0.73 to 
1.01; P = .072) or MCV (OR = 0.88, 95% CI = 0.73 to 1.06; P = .18).
Sensitivity Analyses
The pooled fully adjusted odds ratios and 95% confidence intervals 
were similar to those adjusted only for study matching variables 
(Figure 1). Associations between HPV serological markers and 
esophageal squamous cell carcinoma were robust and did not 
change substantially when we excluded subjects who were seropositive 
for the HPV protein of interest and one or more phylogenetically 
related, potentially cross-reacting proteins from the analysis (data 
not shown). Pooled estimates were largely unaffected by the 
exclusion of data from the largest study (South Africa) or from the 
two studies (Iran and China) in which blood collection procedures 
differed for the case and control subjects (data not shown). There 
were statistically significant interactions between sex and seropos-
itivity for HPV6 L1 (Pinteraction = .025), HPV11 L1 (Pinteraction = .040), 
and HPV35 L1 (Pinteraction = .031), with odds ratios for males of 1.40 
(95% CI = 1.17 to 1.68; P = .0020), 1.49 (95% CI = 1.20 to 1.86; 
P < .001), and 1.13 (95% CI = 0.83 to 1.53; P = .42), respectively, 
and for females, 1.00 (95% CI = 0.78 to 1.27; P = .97), 1.04 (95% 
CI = 0.79 to 1.35; P = .79), and 0.67 (95% CI = 0.47 to 0.96; P = .030), 
respectively, but not for any other HPV serological marker (P 
values ranged from .073 to .86). For the three HPV proteins other 
than HPV6 L1 and HPV11 L1 that were statistically significantly 
associated with esophageal squamous cell carcinoma in the com-
bined sex analysis, there was no statistically significant interaction 
between sex and seropositivity for HPV16 E6 (Pinteraction = .47), 
HPV33 L1 (Pinteraction = .088), and HPV6 E6 (Pinteraction = .61); the sex-
specific odds ratios were 2.03 (95% CI = 1.08 to 3.82; P = .029), 
1.50 (95% CI = 1.08 to 2.09; P = .015), and 2.78 (95% CI = 1.48 to 
5.22; P = .0015), respectively, for males and 1.39 (95% CI = 0.62 
to 3.12; P = .43), 0.97 (95% CI = 0.66 to 1.42; P = .88), and 2.08 
(95% CI = 0.84 to 5.17; P = .11), respectively, for females. No 
statistically significant interactions were found between tobacco 
smoking or alcohol consumption and seropositivity for any of the 
HPV markers (data not shown).
Discussion
In this collaboration of six large case–control studies, we used 
advanced serological methods to detect circulating antibodies 
against a total of 28 HPV antigens (18 L1, E6, or E7 antigens from 
the eight high-risk mucosal HPV types that are most prevalent in 
cervical cancer; six L1, E6, or E7 antigens from two prevalent 
Table 2. Characteristics of case and control subjects in the included studies
Study No. of subjects
Median age,  
y (range)
Female Never smoker Never drinker
High school  
education or  
beyond
Urban  
residence
No. (%) No. (%) No. (%) No. (%) No. (%)
South Africa Control subjects: 1110 59 (26–88) 462 (42) 616 (55) 506 (46) 593 (53) 975 (88)
Case subjects: 697 58 (29–90) 268 (38) 222 (32) 234 (34) 264 (38) 538 (77)
Australia Control subjects: 424 64 (34–80) 182 (43) 209 (49) 57 (13) 424 (100) 271 (64)
Case subjects: 211 64 (34–79) 90 (43) 52 (25) 29 (14) 211 (100) 131 (62)
Central and Eastern Europe Control subjects: 314 59 (39–76) 36 (11) 107 (34) 40 (13) 300 (96) 221 (70)
Case subjects: 157 58 (39–80) 18 (11) 19 (12) 7 (4) 149 (95) 80 (51)
Brazil Control subjects: 314 58 (33–89) 68 (22) 95 (30) 127 (40) 28 (9) 256 (82)
Case subjects: 157 60 (33–91) 34 (22) 24 (15) 30 (19) 7 (4) 96 (61)
Iran Control subjects: 221 65 (31–85) 115 (52) 175 (79) 214 (97) 15 (7) 55 (25)
Case subjects: 220 64 (30–88) 114 (52) 164 (75) 216 (98) 5 (2) 55 (25)
China Control subjects: 119 57 (34–73) 46 (39) 53 (45) 68 (57) 57 (48) 71 (60)
Case subjects: 119 58 (36–70) 46 (39) 53 (45) 71 (60) 75 (63) 63 (53)
All studies Control subjects: 2502 60 (26–89) 909 (36) 1255 (50) 1012 (40) 1417 (57) 1849 (74)
Case subjects: 1561 60 (29–91) 570 (37) 534 (34) 587 (38) 711 (46) 963 (62)
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low-risk mucosal HPV types; and four L1 antigens from cutaneous 
HPV types) and found five nominally statistically significant asso-
ciations with esophageal squamous cell carcinoma risk (ie, HPV16 
E6, HPV33 L1, HPV6 E6, HPV6 L1, and HPV11 L1). Non-
statistically significant but elevated odds ratios were also found for 
the E6 proteins of HPV33 and HPV52.
To our knowledge, seven previous studies have examined the 
associations between esophageal squamous cell carcinoma and 
HPV serological markers (19,31–36). In these studies, the serological 
markers examined for associations with esophageal squamous cell 
carcinoma were HPV16 L1 (all seven studies), HPV18 L1 (32–34), 
HPV33 L1 (33), and HPV73 L1 (32). Four studies found no sta-
tistically significant association between esophageal squamous cell 
carcinoma and HPV16 L1 seropositivity after adjustment for 
various risk factors, with estimated odds ratios of 3.0 (95% CI = 0.6 
to 14) (33), 0.9 (95% CI = 0.3 to 2.4) (34), 0.8 (95% CI = 0.3 to 
2.0) (35), and 1.6 (95% CI = 0.8 to 3.3) (32), whereas three studies 
did, with estimated odds ratios of 1.5 (95% CI = 1.1 to 2.1) (19), 
4.5 (95% CI = 1.8 to 11.9) (36), and 13.1 (95% CI = 1.6 to 108) 
(31). The odds ratio estimates of the latter two studies, although 
appearing somewhat inconsistent with those of the other studies, 
are notable for their high degree of statistical imprecision. The 
pooled odds ratio for HPV16 L1 of 1.20 (95% CI = 0.97 to 1.47) 
estimated in this analysis is relatively small when compared with 
previously observed odds ratios measuring the associations between 
HPV16 L1 seropositivity and squamous cell carcinoma of the 
cervix (OR ~8) (16) and oropharynx (OR ~3.5) (20) but similar in 
magnitude to odds ratios observed for squamous cell carcinoma of 
the oral cavity (OR ~1.5.) (20). Similarly, the statistically significant 
odds ratio of 1.89 (95% CI = 1.09 to 3.29) that we observed for the 
Table 3. Pooled fully adjusted odds ratios for serological markers and esophageal squamous cell carcinoma*
Serological marker†
Seropositive case  
subjects, No. (%)
Seropositive control  
subjects, No. (%) Fully adjusted OR (95% CI) P‡
Mucosal high-risk HPV types    
 HPV16 L1 235 (15.1) 333 (13.3) 1.20 (0.97 to 1.47) .092
 HPV16 E6 34 (2.2) 38 (1.5) 1.89 (1.09 to 3.29) .023
 HPV16 E7 24 (1.5) 49 (2.0) 0.82 (0.46 to 1.46) .50
 HPV16 E6 and/or E7 54 (3.5) 85 (3.4) 1.16 (0.78 to 1.74) .46
 HPV16 E6 and E7§ 4 (0.3) 2 (0.1) 5.57 (0.90 to 34.35) .064
 HPV31 L1 132 (8.5) 237 (9.5) 0.97 (0.75 to 1.25) .82
 HPV31 E6§ 22 (1.4) 34 (1.4) 1.18 (0.66 to 2.10) .58
 HPV33 L1 136 (8.7) 191 (7.6) 1.30 (1.00 to 1.69) .047
 HPV33 E6§ 8 (0.5) 5 (0.2) 2.76 (0.86 to 8.82) .087
 HPV35 L1 142 (9.1) 256 (10.2) 0.97 (0.76 to 1.23) .80
 HPV35 E6§ 18 (1.1) 16 (0.6) 1.49 (0.73 to 3.05) .27
 HPV52 L1 137 (8.8) 217 (8.7) 1.09 (0.85 to 1.41) .49
 HPV52 E6§ 6 (0.4) 3 (0.1) 3.92 (0.92 to 16.74) .065
 HPV58 L1 133 (8.5) 196 (7.8) 1.14 (0.88 to 1.47) .33
 HPV58 E6§ 10 (0.6) 12 (0.5) 1.23 (0.50 to 3.05) .65
 HPV18 L1 546 (35.0) 749 (29.9) 1.28 (0.93 to 1.75) .13
 HPV18 E6§ 26 (1.7) 32 (1.3) 1.24 (0.70 to 2.18) .46
 HPV18 E7§ 13 (0.8) 14 (0.6) 1.31 (0.58 to 2.93) .52
 HPV18 E6 and/or E7§ 37 (2.4) 45 (1.8) 1.21 (0.75 to 1.94) .43
 HPV18 E6 and E7§ 2 (0.1) 1 (0.0) 3.52 (0.31 to 39.48) .31
 HPV45 L1 194 (12.4) 335 (13.4) 0.92 (0.74 to 1.14) .43
 HPV45 E6§ 12 (0.8) 15 (0.6) 1.64 (0.72 to 3.70) .24
Mucosal low-risk HPV types    
 HPV6 L1 688 (44.1) 919 (36.7) 1.22 (1.05 to 1.42) .010
 HPV6 E6§ 41 (2.6) 26 (1.0) 2.53 (1.51 to 4.25) <.001
 HPV6 E7§ 1 (0.1) 3 (0.1) 0.40 (0.04 to 4.09) .44
 HPV11 L1 365 (23.4) 462 (18.5) 1.30 (1.09 to 1.56) .0036
 HPV11 E6§ 15 (1.0) 11 (0.4) 1.99 (0.89 to 4.44) .093
 HPV11 E 7 (0.4) 17 (0.7) 0.55 (0.22 to 1.40) .21
Cutaneous HPV types    
 HPV1 L1 268 (17.2) 406 (16.2) 1.07 (0.88 to 1.30) .48
 HPV4 L1 379 (24.3) 612 (24.5) 1.06 (0.89 to 1.26) .48
 HPV49 L1 427 (27.4) 586 (23.4) 1.18 (1.00 to 1.40) .055
 HPV77 L1 176 (11.3) 281 (11.2) 1.11 (0.88 to 1.39) .39
Other markers    
 p53 266 (17.0) 111 (4.4) 8.10 (3.83 to 17.17) <.001
 JCV VP1 1139 (73.0) 1865 (74.5) 0.86 (0.73 to 1.01) .072
 MCV VP1 1261 (80.8) 2088 (83.4) 0.88 (0.73 to 1.06) .18
* CI = confidence interval; HPV = human papillomavirus; JCV = JC virus; MCV = Merkel cell virus; OR = odds ratio.
† Serological marker data were pooled using a linear mixed effects approach except where otherwise indicated.
‡ All P values two-sided.
§ Serological marker data were pooled using joint fixed effects approach.
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association between esophageal squamous cell carcinoma and 
HPV16 E6 seropositivity is notably smaller than previously 
observed corresponding odds ratios for squamous cell carcinoma 
of the cervix (OR ~146) (17) and oropharynx (OR ~9.9) (20) but 
similar in magnitude to that observed for squamous cell carcinoma 
of the oral cavity (OR ~2.6) (20). Although squamous cell carci-
nomas of the cervix, oropharynx, and oral cavity have also been 
shown to be associated with serum antibodies against HPV16 E7 
(20), we found no statistically significant associations between 
esophageal squamous cell carcinoma and antibodies to E7 for the 
four HPV types tested (ie, HPV16, HPV18, HPV6, and HPV11). 
Additional data suggesting a causal association between HPV16 
and other squamous cell cancers include the strong serological 
response to both the E6 and E7 proteins [squamous cell carcinoma 
of the cervix, OR ~335 (17), the oropharynx, OR ~67 (20), and the 
oral cavity, OR ~4 (20)]. In this study population, we found about 
a sixfold increase in the odds of esophageal squamous cell carci-
noma when antibodies to both HPV16 E6 and E7 were present; 
however, this “double seropositive” response was found in only 
four (0.26%) of 1561 case subjects and in two (0.08%) of 2502 
control subjects in the entire study. Thus, the overall results for 
HPV16 from this study taken together with evidence from previous 
serological studies suggest that if cases of esophageal squamous cell 
carcinoma are caused by HPV16, they must be rare.
The three previous studies that examined the relationship 
between esophageal squamous cell carcinoma and circulating 
HPV18 L1 antibodies found no association (32–34). Consistent 
with these results are the non-statistically significant odds ratios we 
observed in this study for each of the five HPV18 serological 
markers that were assessed. In the only previous study to examine 
the relationship between esophageal squamous cell carcinoma and 
HPV33 L1 antibodies, Bjørge et al. (33) did not find an association. 
This result, however, was based on only 12 HPV33 L1–seropositive 
case subjects, suggesting that there was probably insufficient 
statistical power to detect small to moderate effects. In this study, 
we observed a statistically significant odds ratio of 1.30 (95% CI = 
1.00 to 1.69, P = .047) for HPV33 L1 seropositivity, which is similar 
in magnitude to the non-statistically significant corresponding 
estimated odds ratio of 1.8 (95% CI = 0.4 to 7.2, P = .041) observed 
by Bjørge et al. (33). We did not find a statistically significant 
association between esophageal squamous cell carcinoma and 
seropositivity for HPV33 E6, although the odds ratio was elevated 
(OR = 2.76, 95% CI = 0.86 to 8.82; P = .087). Overall, our findings 
in combination with previous evidence suggest that if HPV33 is a 
MCV VP1
JCV VP1
p53
HPV77 L1
HPV49 L1
HPV4 L1
HPV1 L1
HPV11 E7
HPV11 E6
HPV11 L1
HPV6 E7
HPV6 E6
HPV6 L1
HPV45 E6
HPV45 L1
HPV18 E6 and E7
HPV18 E6 and/or E7
HPV18 E7
HPV18 E6
HPV18 L1
HPV58 E6
HPV58 L1
HPV52 E6
HPV52 L1
HPV35 E6
HPV35 L1
HPV33 E6
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HPV16 E6 and E7
HPV16 E6 and/or E7
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Serological marker
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Adjusted only for study matching variables Fully adjusted
Figure 1. Pooled odds ratios for serological markers and esophageal squamous cell carcinoma adjusted for study matching variables only (left) 
and fully adjusted (right). Circles represent odds ratios, horizontal lines represent 95% confidence intervals, and the vertical lines represent the 
odds ratios of unity for the seronegative referent groups. HPV = human papillomavirus; JCV = JC virus; MCV = Merkel cell virus; OR = odds ratio; 
CI = confidence interval.
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risk factor for esophageal squamous cell carcinoma, it is unlikely to 
be major risk factor.
Whereas our findings for HPV16 and HPV33 are consistent, to 
some degree, with their causative role in other cancers, our findings 
for HPV6 and HPV11 are more difficult to interpret. These HPV 
types are known to cause benign tumors of the larynx and respiratory 
epithelium in children and adolescents (57); however, based on their 
absence as single infections in cervical cancer (14), they are currently 
classified as low-risk types. For this reason and because this study is the 
first to compare the prevalence of low-risk HPV antibodies between 
esophageal squamous cell carcinoma case subjects and control subjects, 
the statistically significant associations we observed for HPV6 E6, 
HPV6 L1, and HPV11 L1 should be viewed as hypothesis-generating 
findings to be confirmed or refuted in further studies.
In addition to HPV serology, another widely used method for 
assessing the role of HPV in esophageal squamous cell carcinoma 
has been to search for HPV DNA in the tissue of the tumors. 
However, the findings from studies using this method have been 
remarkably inconsistent. For example, a review published in 2002 
showed that the proportions of esophageal squamous cell carci-
noma tissues found to contain DNA varied from 0% to 100% 
among studies (26). These proportions varied considerably even 
among the larger studies that examined tissues from the same 
country and that used the same techniques to detect HPV DNA. 
It has been suggested that imperfect tissue handling and processing 
protocols resulting in HPV DNA contamination of esophageal 
squamous cell carcinoma specimens is likely a primary source of 
the between-study variability in the HPV DNA detection rates 
(58). It is worth noting, however, that a recent study that claims to 
have taken extreme care to prevent HPV DNA contamination 
concluded that HPV is not involved in the development of esophageal 
squamous cell carcinoma in China (59).
This study has several limitations. First, although we examined 
the associations between esophageal squamous cell carcinoma and 
32 HPV serological markers (including four E6 and E7 composite 
markers), we did not adjust for multiple comparisons. We believed 
that a better approach, as recommended by others (60–62), was to 
evaluate the results in the context of previous supporting evidence, 
biological plausibility, the number of tests performed, and the 
strengths of the observed associations. However, we acknowledge 
that although the P values were nominal for individual tests, 
the type I error rate for observing one or more false statistically 
significant test results among all tests performed was likely to be 
inflated. Second, all of the contributing studies had a case–control 
design, and thus their results are susceptible to reverse causation. 
Third, we cannot exclude the possibility that some study-specific 
and/or general confounders were not adequately adjusted for in 
this analysis. However, we did attempt to adjust for all previously 
identified study-specific and general confounders as completely as 
was permitted by the available data. Moreover, whereas the possi-
bility of unknown confounding factors can never be completely 
excluded, substantial confounding due to improperly defined 
known confounders appears unlikely given the consistency between 
the minimally and fully adjusted pooled estimates (Figure 1). 
Fourth, because infection with one or more high-risk mucosal 
types of HPV is a necessary cause of cervical cancer (15), estimates 
of the associations between seropositivity to the E6 or E7 proteins 
of the high-risk mucosal HPV types and esophageal squamous cell 
carcinoma for women are vulnerable to confounding if the rates 
of undiagnosed cervical cancers differ between case subjects and 
control subjects. In this study, however, such confounding is likely 
to be small given that we found no statistically significant differences 
between males and females with regard to associations involving 
either E6 or E7 antibodies.
In this serological study, to our knowledge the largest one to date 
to examine the association between esophageal squamous cell carci-
noma and HPV, we found limited evidence of such an association. We 
cautiously describe the evidence as “limited” because the strongest 
evidence of associations (in terms of P values) observed in this study 
were for HPV types that we had relatively low a priori expectations of 
having a causal role in esophageal squamous cell carcinoma (ie, HPV6 
and HPV11). HPV types with which we had higher a priori expecta-
tions of having a causal role showed relatively weak or no evidence of 
an association with esophageal squamous cell carcinoma (eg, HPV16 
and HPV18). We therefore cannot exclude the possibility that our 
statistically significant findings may have been due to chance. 
Although HPV does not appear to be an important risk factor for 
esophageal squamous cell carcinoma, we cannot exclude the possibility 
that certain HPV types may be involved in a small subset of cancers.
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